Primary biliary cholangitis: 2018 Practice Guidance from the American Association for the study of Liver Diseases - Lindor, K. D.; Bowlus, C. L.; Boyer, J.; Levy, C.; Mayo, M. (Hepatology, 2018)

Primary biliary Cirrhosis–presentation and diagnosis - Leuschner, U. (Clin Liver Dis, 2003)

Primary biliary Cirrhosis: survival of a large cohort of symptomatic and asymptomatic patients followed for 24 years - Mahl, T. C.; Shockcor, W.; Boyer, J. L. (J Hepatol, 1994)

Survival and symptom progression in a geographically based cohort of patients with primary biliary Cirrhosis: follow-up for up to 28 years - Prince, M.; Chetwynd, A.; Newman, W.; Metcalf, J. V.; James, O. F. (Gastroenterology, 2002)

Asymptomatic primary biliary Cirrhosis: a study of its natural history and prognosis - Springer, J.; Cauch-Dudek, K.; O’Rourke, K.; Wanless, I. R.; Heathcote, E. J. (Am J Gastroenterol, 1999)

The prognostic importance of clinical and histologic features in asymptomatic and symptomatic primary biliary Cirrhosis - Roll, J.; Boyer, J. L.; Barry, D.; Klatskin, G. (N Engl J Med, 1983)

A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary Cirrhosis - Combes, B.; Carithers, R. L.; Maddrey, W. C.; Lin, D.; McDonald, M. F.; Wheeler, D. E. (Hepatology, 1995)

The Canadian Multicenter Doubleblind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary Cirrhosis - Heathcote, E. J.; Cauch-Dudek, K.; Walker, V.; Bailey, R. J.; Blendis, L. M.; Ghent, C. N. (Hepatology, 1994)

A multicenter, controlled trial of ursodiol for the treatment of primary biliary Cirrhosis. UDCA-PBC Study Group - Poupon, R. E.; Balkau, B.; Eschwege, E.; Poupon, R. (N Engl J Med, 1991)

Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary Cirrhosis - Poupon, R. E.; Lindor, K. D.; Cauch-Dudek, K.; Dickson, E. R.; Poupon, R.; Heathcote, E. J. (Gastroenterology, 1997)

Natural history of primary biliary cholangitis in the Ursodeoxycholic Acid era: role of Scoring systems - Goel, A.; Kim, W. R. (Clin Liver Dis, 2018)

A placebo-controlled trial of obeticholic acid in primary biliary cholangitis - Nevens, F.; Andreone, P.; Mazzella, G. (N Engl J Med, 2016)

A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis - Kowdley, K. V.; Luketic, V.; Chapman, R.; Hirschfield, G. M.; Poupon, R.; Schramm, C. (Hepatology, 2018)

Application of the latest advances in evidence-based medicine in primary biliary cholangitis - Kowdley, K. V.; Bowlus, C. L.; Levy, C.; Mayo, M. J.; Pratt, D. S.; Vuppalanchi, R.; Younossi, Z. M. (Am J Gastroenterol, 2023)

US Food and Drug Administration. Due to risk of serious liver injury, FDA restricts use of Ocaliva (obeticholic acid) in primary biliary cholangitis (PBC) patients with advanced Cirrhosis. https://www.fda.gov/drugs/drug-safety-and-availability/due-risk-serious-liver-injury-fda-restricts-use-ocaliva-obeticholic-acid-primary-biliary-cholangitis.

Factors associated with prevalence and treatment of primary biliary cholangitis in United States health systems - Lu, M.; Li, J.; Haller, I. V. (Clin Gastroenterol Hepatol, 2018)

Increasing prevalence of primary biliary cholangitis and reduced mortality with treatment - Lu, M.; Zhou, Y.; Haller, I. V. (Clin Gastroenterol Hepatol, 2018)

Ursodeoxycholic acid treatment preferentially improves overall survival among African americans with primary biliary cholangitis - Gordon, S. C.; Wu, K. H.; Lindor, K. (Am J Gastroenterol, 2020)

Portal Hypertension in primary biliary cholangitis: prevalence, natural history and histological correlates - Warnes, T. W.; Roberts, S. A.; Smith, A.; Cope, V. M.; Vales, P.; Haboubi, N. Y.; McMahon, R. F. (Eur J Gastroenterol Hepatol, 2021)